Potential of the parasitic wasp Lariophagus distinguendus (FÖRSTER) (Hymenoptera: Pteromalidae) to control the tobacco beetle Lasioderma serricorne (F.) (Coleoptera: Anobiidae)

Die Lagererzwespe Lariophagus distinguendus ist eine generalistische Parasitoidenart, welche die Larven von mindestens 11 verschiedenen Käferarten parasitiert. Die Wirte leben alle entweder endophytisch in Samen oder in Kokons (STEIDLE & SCHÖLLER 1997). Bei der Parasitierung stechen die Weibchen die Samen oder Kokons an und legen jeweils ein Ei an die Außenseite der Wirtslarve (Abb. 1). Die Parasitioidenlarve frisst von außen an dem Wirt, der dabei abgetötet wird. Die Parasitoidenlarve verpuppt sich im Samen oder Kokon, aus dem schließlich eine erwachsene Wespe schlüpft. ...Lariophagus distinguendus (FÖRSTER) (Hymenoptera: Pteromalidae) is a parasitoid of larvae and pupae of a number of beetle species that are pests of stored products. For biological control of the granary weevil Sitophilus granarius (L.) (Coleoptera: Curculionidae) L. distinguendus is currently commercially available in Germany. To study the ability of this strain to parasitize the tobacco beetle and develop on this host, pairs of L. distinguendus were offered larvae of the tobacco beetle of three different age classes. The results reveal that L. distinguendus is able to develop on larvae of the tobacco beetle. Obviously, the oldest larval stage of the beetle is most suitable for development. This makes the strain of L. distinguendus utilised in this experiment generally suitable for the biological control of the tobacco beetle

Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia

Acute myeloid leukemia originates from leukemia-initiating cells that reside in the protective bone marrow niche. CXCR4/CXCL12 interaction is crucially involved in recruitment and retention of leukemia-initiating cells within this niche. Various drugs targeting this pathway have entered clinical trials. To evaluate CXCR4 imaging in acute myeloid leukemia, we first tested CXCR4 expression in patient-derived primary blasts. Flow cytometry revealed that high blast counts in patients with acute myeloid leukemia correlate with high CXCR4 expression. The wide range of CXCR4 surface expression in patients was reflected in cell lines of acute myeloid leukemia. Next, we evaluated the CXCR4-specific peptide Pentixafor by positron emission tomography imaging in mice harboring CXCR4 positive and CXCR4 negative leukemia xenografts, and in 10 patients with active disease. [68Ga] Pentixafor-positron emission tomography showed specific measurable disease in murine CXCR4 positive xenografts, but not when CXCR4 was knocked out with CRISPR/Cas9 gene editing. Five of 10 patients showed tracer uptake correlating well with leukemia infiltration assessed by magnetic resonance imaging. The mean maximal standard uptake value was significantly higher in visually CXCR4 positive patients compared to CXCR4 negative patients. In summary, in vivo molecular CXCR4 imaging by means of positron emission tomography is feasible in acute myeloid leukemia. These data provide a framework for future diagnostic and theranostic approaches targeting the CXCR4/CXCL12-defined leukemia-initiating cell niche

In vivo molecular imaging of chemokine receptor CXCR 4 expression in patients with advanced multiple myeloma

CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination andpoor prognosis. We evaluated the novel CXCR4 probe [$^{68}$Ga]Pentixafor for invivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [$^{68}$Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [$^{68}$Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [$^{18}$F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34$^{+}$ flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [$^{68}$Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases

ARTICLE Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia

A cute myeloid leukemia originates from leukemia-initiating cells that reside in the protective bone marrow niche. CXCR4/CXCL12 interaction is crucially involved in recruitment and retention of leukemia-initiating cells within this niche. Various drugs targeting this pathway have entered clinical trials. To evaluate CXCR4 imaging in acute myeloid leukemia, we first tested CXCR4 expression in patient-derived primary blasts. Flow cytometry revealed that high blast counts in patients with acute myeloid leukemia correlate with high CXCR4 expression. The wide range of CXCR4 surface expression in patients was reflected in cell lines of acute myeloid leukemia. Next, we evaluated the CXCR4-specific peptide Pentixafor by positron emission tomography imaging in mice harboring CXCR4 positive and CXCR4 negative leukemia xenografts, and in 10 patients with active disease. [ 68 Ga]Pentixafor-positron emission tomography showed specific measurable disease in murine CXCR4 positive xenografts, but not when CXCR4 was knocked out with CRISPR/Cas9 gene editing. Five of 10 patients showed tracer uptake correlating well with leukemia infiltration assessed by magnetic resonance imaging. The mean maximal standard uptake value was significantly higher in visually CXCR4 positive patients compared to CXCR4 negative patients. In summary, in vivo molecular CXCR4 imaging by means of positron emission tomography is feasible in acute myeloid leukemia. These data provide a framework for future diagnostic and theranostic approaches targeting the CXCR4/CXCL12-defined leukemia-initiating cell niche